uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 6,217 Shares

uniQure N.V. (NASDAQ:QURE) CFO Christian Klemt sold 6,217 shares of uniQure stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $148,337.62. Following the transaction, the chief financial officer owned 211,513 shares of the company’s stock, valued at $5,046,700.18. The trade was a 2.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

uniQure Stock Performance

NASDAQ:QURE traded down $1.48 on Friday, hitting $15.63. The company’s stock had a trading volume of 5,970,449 shares, compared to its average volume of 2,439,526. uniQure N.V. has a one year low of $7.76 and a one year high of $71.50. The firm has a market capitalization of $973.62 million, a P/E ratio of -3.56 and a beta of 0.66. The stock has a fifty day moving average of $23.62 and a two-hundred day moving average of $29.58. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

Wall Street Analysts Forecast Growth

Several research firms have commented on QURE. Cantor Fitzgerald reiterated an “overweight” rating on shares of uniQure in a report on Wednesday, January 14th. Wolfe Research initiated coverage on shares of uniQure in a research note on Monday. They issued a “peer perform” rating on the stock. Benchmark reissued a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Finally, Mizuho decreased their target price on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, December 8th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $58.33.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Unusual bullish options flow — heavy call buying (24,345 calls, ~181% above typical volume) suggests some traders are speculating on a near‑term rebound or event‑driven move.
• Negative Sentiment: Fresh FDA controversy: coverage highlights critical comments from FDA leadership about uniQure’s rejected rare‑disease therapy, which markets see as increasing regulatory risk for the program. uniQure: Shares Tumble On Fresh FDA Controversy – What Investors Should Know
• Negative Sentiment: FDA commissioner comments drew broad media coverage and were cited as the main driver of the selloff, amplifying short‑term downside as investors reassess approval odds. UniQure plummets as FDA’s Marty Makary disparages rejected rare disease drug
• Negative Sentiment: Multiple securities‑class action filings and firm notices: several law firms are publicizing suits or seeking lead plaintiffs for alleged misstatements during a specified class period — increasing legal and reputational risk and likely weighing on sentiment. Representative notices: DJS Law Group. uniQure N.V. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – QURE
• Negative Sentiment: Broad wave of law‑firm alerts and reminder notices (Rosen, Pomerantz, Faruqi, Robbins, Berger Montague, etc.) highlights that litigation momentum is building and that April 13, 2026 lead‑plaintiff deadlines are approaching — an added near‑term overhang. Example: Rosen Law Firm reminder. ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action – QURE
• Negative Sentiment: Market reaction summaries: analyst/news pieces attribute a large intraday drop to the FDA remarks and resulting uncertainty, reinforcing negative sentiment. Why Is uniQure Stock Down 30% Today?

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in QURE. Avoro Capital Advisors LLC raised its position in shares of uniQure by 38.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares in the last quarter. Aberdeen Group plc grew its position in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares in the last quarter. State Street Corp increased its stake in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares during the period. JPMorgan Chase & Co. raised its holdings in uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in uniQure in the 2nd quarter valued at $29,217,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.